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Between 1994 and 2001， 80 patients underwent radical prostatectomy without adjuvant therapy 
for clinical stage B and C prostate cancer. The patients were not treated with adjuvant therapy before 
biochemical prostate specific antigen (PSA) failure. Of al 80 patients， 35 patients (43.8%) received 
町 oadjuvanthormonal therapy prior to radical prostatectomy (the neoadjuvant therapy group)， 45 
patients (56.2%) underwent prostatectomy alone (the surgerγalone group). Retrospective analysis to 
evaluate the effects of neoadjuvant therapy was performed from clinicopathological findings and the 
biochemical PSA failure-free rate. 
Ofall patients， 58 (72.5%) were in clinical stage B and 22 (27.5%) were in clinical stage C. Of58 
patients in clinical stage B， 19(32.8%) underwent prostatectomy combined with neoadjuvant therapy. 
Ofthe 22 patients in clinical stage C， 17(77.3%) underwent prostatectomy combined with neoadjuvant 
therapy. Pathologically， 37 (46.3%) were in stage B， 38 (47.5%) in stage C and 2'(2.5%) in stage Dl. 
Three patients in the neoadjuvant therapy group had no malignant findings in specimens of 
prostatectomy. In comparison with the clinical stage， pathologically 8 (22.9%) showed overstaging， 4 
(5.0%) understaging and 23 (28.8%) accurate staging in the 町 oadjuvanttherapy group， respectively， 
0(0.0%)，20 (44.4%)， and 25 (55.6%) in the surgery alonegroup. In clinical stage B and C， there was 
no significant difIとrencein the biochemical PSA failure-free rate between the neoadjuvant therapy 
group and the surgerγalone group. On the other hand， inpathological stages B， the 5-year PSA 
failure-free rate was 63.2% in the neoadjuvant therapy group， but 100% in the surgery alone group. 
Although neoadjuvant therapy may have some effect on downstaging， our retrospective analysis 
suggests that it has no significant effect on PSA failure-free rate. 
(Acta Urol. Jpn. 49・515-520，2003) 




Gleason score， stage， performance status (PS)，そ
れぞれの治療の合併症などを考慮し，治療法が選択，



































単独群では， Bが40例， Cが5例であった (Table
1). 
ネオアジュパント療法の内容は LH-RHagonist単
独が最も多く， 20例 (57.1%)，ついで LH-RHago-
nistとフルタミドが8例 (22.9%)，LH-RH agonist 
とピカルタミドが3例 (8.6%)であった.施行期間
は2-32カ月，平均6.8カ月であった.















1 )臨床病期と病理学的病期の比較 (Table1) 
前立腺全摘除術全体の術後病理学的病期はB:37例








ける understagingは， 16.7% (3118)， 5.9% (1/17) 
であった.また， overstagingか，ネオアジュノTント
Table 1. Comparison between clinical and pathological stage 
NT group (n=35) SA group (n=45) 
Clinical stage Clinical stage Total 
B C B C 
Ca(一) 3 O O O 3 
B 12 5 20 O 37 Pathological stagc 
C 3 I1 19 5 38 
DI 。 O 2 
Total 18 17 40 5 80 
Accurate staging 12 (66.7%) 1 (64.7%) 20 (50.0%) 5 (100.0%) 
Understaging 3 (16.7%) 1 ( 5.9%) 20 (50.0%) o ( 0.0%) 
Overstaging or downstage 3 (16.7%) 5 (29.4%) 0(0.0%) o ( 0.0%) 
NT group; ncoadjuvant therapy group， SA group ; surgery alone group. 
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Tab!e 2. Characteristics of patients by treatment group in clinica! stage B and C 
Clinical stage B (n=58) Clinical stage C (n=22) 
NT group (n= 18) SA group (n=40) p value NT group (n=17) SA group (n=5) p value 
Age 66.9 i: 1.3 65.8士0.8 0.369 64.3 i: 1.2 67.8土 0.4 0.0921 
Pretreatment PSA 
Mean土SE 10.02士1.62 10.35土1.46 0.872 52.90 i: 21.96 2 1.75 i:12目78 0.428 
Gleason score 
2-6 8 20 0.960 3 O 0.556 
7 5 15 4 
8-10 2 5 10 4 
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Fig. l-a. PSA failure-free rate after radical 
prostatectomy for clinical stage B. 
73.2%であった.ネオアジムパント療法群と手術単独
群で， PSA非再発率に有意な差は認められなかった
















SA group : n=5 
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NTgroup;N帥 adjuvaotThe..py group， SA group; Surgery A10De group 
Fig. I-b. PSA failure-free rate a丘er radical 
prostatectomy for clinical stage C. 
Table 3. Characteristics of patients by treatment group in pathological stage B and C 
Pathological stage B (n=37) Pathological stage C (n=38) 
NT group (n=17) SA group (n=20) p value NT group (n=14) SA group (n=24) p value 
Age 65.8 土1.2 66目5 土1.4 0_407 65.6 i: 1.2 66.3 i:0.6 0.728 
Pretreatment PSA 
Mean土SE 15.716i:4.303 5.635 i: O. 709 0.010 41.46土20.83 15_08i:2.23 。目090
Gleason score 
2-6 10 15 0.361 5 0_201 
7 4 4 5 12 
8-10 3 8 7 













(4/35)， 44.4% (20/45) であった.一方 2群の
overstaging あるいは，ネオアジュパント療法によ




































SA group : 0=20 
NT group: 0=17 
8 Y回開
NTgroup;N帥 adjuv岨 tTherapy group • SA Bl・up;Su唱.eryA100e group 
Fig. 2・a. PSA failure-free rate after radical 























NT group : 0=14 
』
8 Y曲目
NTgroup;N伺 adjuvaotTherapy group • SA group;Sur盲目'yA100e group 
Fig. 2-b. PSA failure-free rate after radical 
prostatectomy for pathological stage 
C. 





















り，経直腸的 MRIなどが試みられている 3) しか
し，画像診断だけでは正診率改善に限界があるため，








































understagingは11.4% (4/35) 44.4% (20/45) で
あった.一方， overstaging あるいは，ネオアジ」
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